Press Releases

Alpha Mannosidosis Market Top Agendas, Services, Applications, Workforce & Restraints To 2022-2030

Share This Article

According to the report, the global alpha mannosidosis market was valued at US$ 7.6 Mn in 2018 and is anticipated to expand at a CAGR of 9.9% from 2019 to 2030

The global alpha mannosidosis market for the historical period 2017–2018 and forecast period 2019–2027, market exclusivity for orphan drugs, increasing investment in rare disease treatment, and faster market access are projected to drive the global alpha mannosidosis market during the forecast period

Get the sample copy of report@

Market Exclusivity for Orphan Drugs and Increasing Investment in Rare Disease Treatment: Key Drivers

The most important financial incentive of orphan drug approval for pharmaceutical companies is the market exclusivity of several years for products that have been designated as orphan drugs.

This allows pharmaceutical companies to recover costs incurred in development, as during this period regulatory agencies cannot approve a generic equivalent of the drug for the same rare indication.

In the U.S., the period for market exclusivity for orphan drugs is 7 years and in the EU it is 10 years. Similar incentives exist in Japan and Australia, among other major regions

Smaller clinical trial size, shorter trial time, and commercial benefits such as fast track approval, and fee waivers attract multinational corporations to invest in the rare disease segment

The regulatory environment has been more advantageous for developers since the passage of the 1983 Orphan Drug Act. Moreover, venture capitalists see the legislative incentives as a major opportunity to create returns on their investments

Moreover, saturation of the markets for diseases with large patient populations, such as asthma, diabetes and hypertension, has led to the focus of pharmaceutical industry towards more specialist, niche diseases where the unmet need is more substantial and the barriers to entry are much lower.

Fee Reductions & Tax Credits Boost Market Growth

Orphan drug designation qualifies the orphan drug manufacturer to claim tax credits of up to 50% of R&D costs incurred during the clinical trial phase in the U.S.

According to a study conducted by the U.S. Congress, Office of Technology Assessment (OTA, 1993), overall the tax credit lowers the cost of the extra dollar of clinical orphan research by 24% compared to cost without tax credit

Similar incentives include FDA fee waivers that reduces transaction cost associated with the approval process

Therefore, fee reductions & tax credits is likely to increase demand for alpha mannosidosis globally

High Cost of Treatment to Hamper Market

The most important barrier in this market is high cost of producing an orphan drug. The number of patients eligible to receive an orphan drug confines a company’s ability to recover its R&D investment.

Manufactures require incentives to develop orphan drugs. This being a narrow market, profit is based on supply and demand. By order of magnitude, these orphan drugs are more expensive.

View full report@

High investment involved in research and costs incurred for production of recombinant enzymes, increases cost of ERT. The per year treatment cost of a single lysosomal storage disorder patient is several hundred thousand dollars. Also, such high costs are acceptable in developed countries with established reimbursement structure however, in underdeveloped countries these are unaffordable and limits the access.

Global Alpha mannosidosis Market: Competitive Landscape

This report profiles major players in the global alpha mannosidosis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global alpha mannosidosis market is highly consolidated, with the presence of very few players

The only player operating in the global alpha mannosidosis market is Zymenex A/S

Key Questions Answered in Global Alpha mannosidosis Market Report

  • What is the scope of growth of product companies in the global alpha mannosidosis market?
  • What will be the Y-o-Y growth of the global alpha mannosidosis market between 2019 and 2027?
  • What is the influence of changing trends in technologies on the global alpha mannosidosis market?
  • Will North America continue to be the most profitable market for alpha mannosidosis providers?
  • Which factors are anticipated to hamper the growth of the global alpha mannosidosis market during the forecast period?
  • Which are the leading companies in the global alpha mannosidosis market?

Purchase Complete Report Now@

Global Alpha mannosidosis Market – Segmentation

Treatment Type

  • Bone Marrow Transplant
  • Enzyme Replacement Therapy


  • Type I
  • Type II
  • Type III


  • Hospitals
  • Specialty Clinics


  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


1. Preface

2. Executive Summary

3. Research Methodology

4. Market Overview

4.1. Introduction

4.2. Market Dynamics

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Opportunity

4.3. Alpha Mannosidosis Market Analysis and Forecasts, 2019-2030

4.4. Porter’s Five Force Analysis

4.5. Alpha Mannosidosis Market: Value Chain Analysis

4.6. Alpha Mannosidosis Market: Pricing Analysis

5. Alpha Mannosidosis Market Revenue (US$ Mn), 2019-2030

6. Alpha Mannosidosis Market Revenue (US$ Mn), By Treatment, 2019-2030

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Alpha Mannosidosis Market Value Share Analysis, By Treatment, 2019 & 2030

6.4. Alpha Mannosidosis Market By Treatment, 2019 & 2030

6.4.1. Bone Marrow Transplant

6.4.2. Enzyme Replacement Therapy

6.5. Alpha Mannosidosis Market Attractiveness By Treatment,

6.6. Key Trends

7. Alpha Mannosidosis Market Revenue (US$ Mn), By Indication, 2019-2030

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Alpha Mannosidosis Market Value Share Analysis, By Indication, 2019 & 2030

7.4. Alpha Mannosidosis Market By Indication, 2019 & 2030

7.4.1. Type I

7.4.2. Type II

7.4.3. Type III

7.5. Alpha Mannosidosis Market Attractiveness By Indication

7.6. Key Trends

8. Alpha Mannosidosis Market Revenue (US$ Mn), By End-user 2019-2030

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Alpha Mannosidosis Market Value Share Analysis, By End-user, 2019 & 2030

8.4. Alpha Mannosidosis Market By End-user, 2019 & 2030

8.4.1. Hospitals

8.4.2. Specialty Clinics

8.5. Alpha Mannosidosis Market Attractiveness By End-user

8.6. Key Trends

9. Alpha Mannosidosis Market Revenue (US$ Mn), By Geography, 2019-2030

10. North America Alpha Mannosidosis Market Revenue (US$ Mn), 2019-2030


Purchase Complete Report Now@

You can place an order or ask any questions, please feel free to contact | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

Related Articles

Back to top button